Chief Compliance Officer at Oregon Board of Pharmacy
Employing Organization
Team
Decision makers at Oregon Board of Pharmacy
Executive Director
Key decision makers in the same organization
Organization Signals
Board meetings, strategic plans, and buyer signals from Joe Ball’s organization
The committee held a special meeting to discuss and review formulary and protocol items. The key discussion topics included the review and recommendation to the Oregon Board of Pharmacy of revised vaccine protocols for Influenza and Respiratory Syncytial Virus, as well as proposed amendments to the Oregon Administrative Rule regarding services and prescribing protocols.
The rulemaking hearing focused on proposed amendments to various Oregon Administrative Rules (OAR). Key topics included revisions to therapy continuation protocols for opioid use disorder medications, updates to drug compounding definitions and compliance requirements for various facility types, and the incorporation of updated standards by reference for multiple rule sets, including pharmacy practice and professional accreditation standards. The hearing provided an opportunity for public comment on these proposed rules, though no oral testimony was presented.
Extracted from official board minutes, strategic plans, and video transcripts.
Find verified emails, direct dials, role context, job-change updates, and organization signals across every public-sector account you sell to.
Verified emails & phones
Accuracy-guaranteed data
Job-change & title updates
Never lose a contact
The Board meeting centered on the development and review of pharmacy practice protocols. A primary agenda item was amending the continuation of therapy protocol to comply with Senate Bill 236, which required repealing specific language established under previous legislation. The Board also reviewed new protocols for the initiation of care for Opioid Use Disorder, discussing the pathway for pharmacists to prescribe medications for opioid use disorder. The discussion covered mandatory training requirements for pharmacists to prescribe controlled substances, the utilization of trauma-informed patient intake forms to reduce stigma, and the potential impact of these expanded services on increasing patient access to treatment in underserved areas.
The Board conducted executive sessions to deliberate on disciplinary cases and receive legal advice. Key agenda items included the adoption of temporary rules regarding therapy protocols for emergency insulin refills and medications for opioid use disorder. The Board engaged in extensive voting on disciplinary actions for various licensees, resulting in the granting or revocation of licenses and the imposition of civil penalties. Additionally, the Board discussed the potential development of a legislative concept regarding the use of unlicensed personnel in pharmacies, reviewed results from the Uniform MPJE survey, and received updates on legislative, financial, and strategic planning initiatives. Approvals were also granted for board member attendance at upcoming national conferences.
Organization signals
Board meetings and buying signals
Salesforce & HubSpot sync
Native two-way integration
